Acutaas Chemicals Limited has informed the Exchange about Investor Presentation
ACUTAAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Acutaas Chemicals reported strong Q1 FY26 (ended June 30, 2025) results, with revenue rising 17.3% year-on-year to ₹2,072 crore driven by robust growth in the Advanced Pharmaceutical Intermediates segment. EBITDA jumped 72.4% to ₹509 crore, with margins expanding sharply from 16.7% to 24.6%, helped by cost improvements and a favourable product mix. Profit after tax surged nearly 3x to ₹440 crore, with PAT margin improving to 21.2% from 8.3% in the year-ago quarter. Both pharma facilities have received PMDA GMP certification, and the company announced a joint venture in South Korea to tap semiconductor markets. Management guided for 25% revenue growth with improved margins for FY26, citing strong momentum across CDMO, battery chemicals, and semiconductors.
The sharp margin expansion and management's growth-plus-margin guidance are positive signals for shareholders, supported by strong ROCE of 30.7% and ROE of 27.0%. However, the Specialty Chemicals segment declined 1.8% YoY, which investors should watch.